First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial Meeting Abstract
| Authors: | Porta, C. G.; Burotto, M.; Suarez Rodriguez, C.; Bourlon, M. T.; Hsieh, J.; Shah, A. Y.; Hamzaj, A.; Bedke, J.; Pook, D.; Kessler, R.; Tomita, Y.; Drakaki, A.; Zhang, J.; Simsek, B.; Schwab, G.; Escudier, B.; Motzer, R. J.; Choueiri, T. K.; Apolo, A. B.; Powles, T. B. |
| Abstract Title: | First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S688 |
| End Page: | S689 |
| Language: | English |
| ACCESSION: | WOS:000700527701129 |
| DOI: | 10.1016/j.annonc.2021.08.059 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 663P -- Source: Wos |
